CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel’s Clinical Sciences team, in the Neurogastroenterology & Mortility journal. Dr. English participated in a study of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome. Other contributors included Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart Turner, Fabio Cataldi, Donald Lipkis, and Tack Jan. The study aimed to assess the efficacy and safety of olorinab (IBS-D) and constipation (IBS-C).
News at CenExel
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high placebo response has been shown to be increasing as time progresses (Kemp et al., 2010; Loebel et al., 2010; Rief et al., 2009; Tuttle et al., 2015), with such ramifications as several pharma companies reducing or closing their psychiatric as well as general medicine R&D, increased costs for drug development, more inconclusive and failed trials, and delays in the development of new medications (Alphs et al., 2012).
Analgesic efficacy and safety of naproxen sodium versus hydrocodone / acetaminophen in acute postsurgical dental pain
Analgesic efficacy and safety of naproxen sodium versus hydrocodone / acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial Stephen A. Cooper (1), Paul J. Desjardins (2), Todd Bertoch (3), Engy Mikhail (4), Sistine...
According to the Center for Disease Control, the Human Papilloma virus (HPV) is the most common sexually transmitted disease in the United States, and it affects more than 20 million people each year. In fact, it is so common that at least 50% of the population who...